LACRIFLOW is a self-retaining (DON’T need to tie) lacrimal stent for Common Canaliculus Obstruction (CCO) and Nasolacrimal Duct Obstruction (NLDO), with enhanced flexibility and hydrophilic coating for doctor ease and patient comfort.
The LACRIFLOW is indicated in treatments of epiphora in patients 12 months and older, in cases of:
- Canalicular pathologies (stenosis, obstruction, lacerations)
- During Dacryocystorhinostomy (conventional or laser)
- Congenital nasolacrimal duct obstruction
LAWS AND REGULATIONS
・JAPAN: Pharmaceutical and Medical Device Act (PMD Act) approval
・USA: FDA 510k clearance
・Other countries: Please contact through company website.